Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yumeng Lu

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Global Change Biology|April 7, 2023
Tracing the future of epidemics: Coincident niche distribution of host animals and disease incidence revealed climate-correlated risk shifts of main zoonotic diseases in ChinaBo Cao, Chengke Bai, Kunyi Wu, et al.
Annals of Hematology|June 3, 2019
The abnormal function of CD39<sup>+</sup> regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopeniaYumeng Lu, Luya Cheng, Feng Li, et al.
Plant, Cell & Environment|September 11, 2025
The Transcription Factor MYB8 Positively Regulates Flavonoid Biosynthesis of Scutellaria baicalensis in Response to Drought StressChong Chen, Xiaofang Zhou, Bo Cao, et al.
Cancer Medicine|November 9, 2023
TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damageShuaikang Chang, Wenqin Xiao, Yongsheng Xie, et al.
Acta Biochimica Et Biophysica Sinica|April 6, 2021
Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathwayKe Hu, Bo Li, Ruye Ma, et al.
Neoplasia (New York, N.Y.)|December 10, 2021
DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathwayShuaikang Chang, Bo Li, Yongsheng Xie, et al.
International Immunopharmacology|December 29, 2023
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatoryHui Zhang, Ke Hu, Yumeng Lu, et al.
International Immunopharmacology|November 1, 2023
Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cellsQilin Feng, Ke Hu, Huifang Hu, et al.
International Immunopharmacology|June 22, 2024
Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139]Qilin Feng, Ke Hu, Huifang Hu, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 11, 2020
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastropheLiangning Hu, Bo Li, Gege Chen, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Global Change Biology|April 7, 2023
Tracing the future of epidemics: Coincident niche distribution of host animals and disease incidence revealed climate-correlated risk shifts of main zoonotic diseases in ChinaBo Cao, Chengke Bai, Kunyi Wu, et al.
Annals of Hematology|June 3, 2019
The abnormal function of CD39<sup>+</sup> regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopeniaYumeng Lu, Luya Cheng, Feng Li, et al.
Plant, Cell & Environment|September 11, 2025
The Transcription Factor MYB8 Positively Regulates Flavonoid Biosynthesis of Scutellaria baicalensis in Response to Drought StressChong Chen, Xiaofang Zhou, Bo Cao, et al.
Cancer Medicine|November 9, 2023
TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damageShuaikang Chang, Wenqin Xiao, Yongsheng Xie, et al.
Acta Biochimica Et Biophysica Sinica|April 6, 2021
Anti-DLBCL efficacy of DCZ0825 in vitro and in vivo: involvement of the PI3K‒AKT‒mTOR/JNK pathwayKe Hu, Bo Li, Ruye Ma, et al.
Neoplasia (New York, N.Y.)|December 10, 2021
DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathwayShuaikang Chang, Bo Li, Yongsheng Xie, et al.
International Immunopharmacology|December 29, 2023
A novel pterostilbene compound DCZ0825 induces macrophage M1 differentiation and Th1 polarization to exert anti-myeloma and immunomodulatoryHui Zhang, Ke Hu, Yumeng Lu, et al.
International Immunopharmacology|November 1, 2023
Berberine derivative DCZ0358 induce oxidative damage by ROS-mediated JNK signaling in DLBCL cellsQilin Feng, Ke Hu, Huifang Hu, et al.
International Immunopharmacology|June 22, 2024
Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139]Qilin Feng, Ke Hu, Huifang Hu, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 11, 2020
A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastropheLiangning Hu, Bo Li, Gege Chen, et al.
Pageof 3